These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 7529921)

  • 1. [Influence of the granulocyte growth factor on the cost of bone marrow autografts in oncologic hematology].
    Brice P; Godin S; Libert O; Marolleau JP; Makki J; Extra JM; Faure P; Gisselbrecht C
    Presse Med; 1994 Oct; 23(33):1512-5. PubMed ID: 7529921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of G-CSF-primed peripheral blood progenitor cells and bone marrow auto transplantation: clinical assessment and cost-effectiveness.
    Faucher C; le Corroller AG; Blaise D; Novakovitch G; Manonni P; Moatti JP; Maraninchi D
    Bone Marrow Transplant; 1994 Dec; 14(6):895-901. PubMed ID: 7536070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative cost of allogeneic or autologous bone marrow transplantation and chemotherapy in patients with acute myeloid leukaemia in first remission.
    Dufoir T; Saux MC; Terraza B; Marit G; Guessard S; Foulon G; Reiffers J
    Bone Marrow Transplant; 1992 Oct; 10(4):323-9. PubMed ID: 1422487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of lenograstim on the cost of autologous bone marrow transplantation. A preliminary communication.
    Brice P; Godin S; Libert O; Marolleau JP; Makki J; Extra JM; Faure P; Gisselbrecht C
    Pharmacoeconomics; 1995 Mar; 7(3):238-41. PubMed ID: 10155313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness of pegfilgrastim versus filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma: an economic evaluation of the PALM Trial.
    Perrier L; Lefranc A; Pérol D; Quittet P; Schmidt-Tanguy A; Siani C; de Peretti C; Favier B; Biron P; Moreau P; Bay JO; Lissandre S; Jardin F; Espinouse D; Sebban C
    Appl Health Econ Health Policy; 2013 Apr; 11(2):129-38. PubMed ID: 23435861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The additive effect of peripheral blood stem cells, harvested with low-dose cyclophosphamide, to autologous bone marrow reinfusion on hematopoietic reconstitution after ablative chemotherapy in breast cancer patients with localized disease.
    de Graaf H; Mulder NH; Willemse PH; van der Graaf WT; Sleijfer DT; Zijlstra JG; Elias M; Sibinga CT; Vellenga E; de Vries EG
    Anticancer Res; 1995; 15(6B):2851-6. PubMed ID: 8669878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of G-CSF or GM-CSF mobilized peripheral blood progenitor cells (PBPC) alone or to augment marrow as hematologic support of single or multiple cycle high-dose chemotherapy.
    Elias AD; Ayash L; Tepler I; Wheeler C; Schwartz G; Mazanet R; Schnipper L; Frei E; Antman K
    J Hematother; 1993; 2(3):377-82. PubMed ID: 7522891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of autologous bone marrow transplantation.
    Lawless GD
    Am J Health Syst Pharm; 1995 Oct; 52(19 Suppl 4):S11-4. PubMed ID: 8846240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost analysis of the introduction of PBPC for autologous transplantation: effect of switching from bone marrow (BM) to peripheral blood progenitor cells (PBPC).
    Bredeson C; Malcolm J; Davis M; Bence-Bruckler I; Kearns B; Huebsch L
    Bone Marrow Transplant; 1997 Nov; 20(10):889-96. PubMed ID: 9404932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytokine-primed bone marrow stem cells vs. peripheral blood stem cells for autologous transplantation: a randomized comparison of GM-CSF vs. G-CSF.
    Weisdorf D; Miller J; Verfaillie C; Burns L; Wagner J; Blazar B; Davies S; Miller W; Hannan P; Steinbuch M; Ramsay N; McGlave P
    Biol Blood Marrow Transplant; 1997 Oct; 3(4):217-23. PubMed ID: 9360784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid engraftment after autologous transplantation utilizing marrow and recombinant granulocyte colony-stimulating factor-mobilized peripheral blood stem cells in patients with acute myelogenous leukemia.
    Demirer T; Buckner CD; Appelbaum FR; Petersen FB; Rowley S; Weaver CH; Lilleby K; Sanders J; Chauncey T; Storb R
    Bone Marrow Transplant; 1995 Jun; 15(6):915-22. PubMed ID: 7581091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Administration of human recombinant granulocyte colony-stimulating factor (filgrastim) accelerates granulocyte recovery following high-dose chemotherapy and autologous marrow transplantation with 4-hydroperoxycyclophosphamide-purged marrow in women with metastatic breast cancer.
    Kennedy MJ; Davis J; Passos-Coelho J; Noga SJ; Huelskamp AM; Ohly K; Davidson NE
    Cancer Res; 1993 Nov; 53(22):5424-8. PubMed ID: 7693341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Granulocyte-macrophage colony-stimulating factor accelerates hematopoietic recovery after autologous bone marrow or peripheral blood progenitor cell transplantation and high-dose chemotherapy for lymphoma.
    Colombat P; Delain M; Desbois I; Domenech J; Binet C; Tabah I; Lamagnere JP; Linassier C
    Bone Marrow Transplant; 1996 Aug; 18(2):293-9. PubMed ID: 8864437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. G-CSF administration following peripheral blood progenitor cell (PBPC) autograft in lymphoid malignancies: evidence for clinical benefits and reduction of treatment costs.
    Tarella C; Castellino C; Locatelli F; Caracciolo D; Corradini P; Falda M; Novarino A; Tassi V; Pileri A
    Bone Marrow Transplant; 1998 Feb; 21(4):401-7. PubMed ID: 9509976
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose ifosfamide/carboplatin/etoposide: maximum tolerable doses, toxicities, and hematopoietic recovery after autologous stem cell reinfusion.
    Fields KK; Elfenbein GJ; Perkins JB; Janssen WE; Ballester OF; Hiemenz JW; Zorsky PE; Kronish LE; Foody MC
    Semin Oncol; 1994 Oct; 21(5 Suppl 12):86-92. PubMed ID: 7527592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-analysis of randomized controlled trials of prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor after autologous and allogeneic stem cell transplantation.
    Dekker A; Bulley S; Beyene J; Dupuis LL; Doyle JJ; Sung L
    J Clin Oncol; 2006 Nov; 24(33):5207-15. PubMed ID: 17114653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized comparison of G-CSF + GM-CSF vs G-CSF alone for mobilization of peripheral blood stem cells: effects on hematopoietic recovery after high-dose chemotherapy.
    Spitzer G; Adkins D; Mathews M; Velasquez W; Bowers C; Dunphy F; Kronmueller N; Niemeyer R; McIntyre W; Petruska P
    Bone Marrow Transplant; 1997 Dec; 20(11):921-30. PubMed ID: 9422470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
    Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
    Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased serum levels of granulocyte colony-stimulating factor after autologous bone marrow or blood stem cell transplantation.
    Haas R; Gericke G; Witt B; Cayeux S; Hunstein W
    Exp Hematol; 1993 Jan; 21(1):109-13. PubMed ID: 7678083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer.
    Nemunaitis J; Rabinowe SN; Singer JW; Bierman PJ; Vose JM; Freedman AS; Onetto N; Gillis S; Oette D; Gold M
    N Engl J Med; 1991 Jun; 324(25):1773-8. PubMed ID: 1903847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.